Quick Dispatch:
Your tirzepatide surmount 2 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount 2 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about tirzepatide surmount 2 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount 2 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
Tirzepatide Delivers in SURMOUNT-2
27.98
SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes
25.19
Tirzepatide Scores Win in Second Obesity Trial, SURMOUNT-2
25.78
Tirzepatide for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity
20.47
01200-X/asset/f2ef2727-f32c-4146-a724-f0b9312e4d9f/main.assets/gr1_lrg.jpg)
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
27.41
Lilly Shows Tirzepatide Superiority in SURMOUNT-3 and 4
21.89
Lilly released results for SURMOUNT-2, a weight loss trial of tirzepatide in people with T2D and obesity or overweight at 72 weeks: 🔘10 mg: -13.4% BW 🔘15 mg: -15.7% BW ⭐️Important: at
27.81
